Monitor for any subsequent collaboration or licensing agreement between Eli Lilly and TRex Bio, as this large pre-IPO investment often precedes a strategic partnership. Watch for Lilly's future 13D filings for any change in intent.
Price Chart
Executive Summary
Eli Lilly & Co. filed a Form 3 initial statement of beneficial ownership disclosing a 5,480,872-share stake in TRex Bio, Inc., consisting of shares issuable upon mandatory conversion of preferred stock and shares purchased in TRXB's IPO. This signals a significant strategic investment by a major pharmaceutical company in a pre-commercial biotech, which is a strong endorsement of TRex Bio's pipeline.
Key Facts
- Eli Lilly & Co. reported beneficial ownership of 5,480,872 shares of TRex Bio common stock.
- The stake includes 4,605,872 shares issuable upon mandatory conversion of convertible preferred stock and 875,000 shares purchased in the IPO.
- Filing date is October 8, 2026, concurrent with or shortly after TRXB's IPO.
Financial Impact
Eli Lilly's stake represents a substantial ownership position in TRex Bio, valued at the IPO price times 5.48M shares. The exact dollar amount is not disclosed in the filing.
Risk Factors
- TRex Bio is a pre-commercial biotech with no approved products, carrying high clinical and regulatory risk.
- Eli Lilly's stake may be passive; the filing does not indicate board representation or active involvement.
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0000059478-26-000094 |
| Document: 0000059478-26-000094-index.html | 0000059478-26-000094 |
| Document: 0000059478-26-000094.txt | 0000059478-26-000094 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | SC 13G | $14.80 $14.44 | ▼ −2.43% | ▼ −2.77% | $13.87 (−6.28%) |
Oct 16, 2026 10d ago | SC 13D | $14.80 $14.44 | ▼ −2.43% | ▼ −2.77% | $13.87 (−6.28%) |
Oct 16, 2026 10d ago | SC 13D | $14.01 $14.80 | ▲ +5.64% | ▲ +5.22% | $13.87 (−1.00%) |
Oct 15, 2026 11d ago | Insider Cluster | $14.01 $14.80 | ▲ +5.64% | ▲ +5.22% | $13.87 (−1.00%) |
Oct 15, 2026 11d ago | SC 13G | $14.16 $14.01 | ▼ −1.06% | ▲ +0.05% | $13.87 (−2.05%) |
Oct 13, 2026 13d ago | Press Release | $13.50 $14.16 | ▲ +4.89% | ▲ +4.60% | $13.87 (+2.74%) |
Oct 9, 2026 17d ago | 424B4 | $14.03 $13.60 | ▼ −3.06% | ▼ −3.05% | $13.87 (−1.14%) |
Oct 9, 2026 18d ago | EFFECT | $14.00 $14.03 | ▲ +0.21% | ▲ +0.27% | $13.87 (−0.93%) |
Oct 8, 2026 18d ago | 3 | $14.00 $14.03 | ▲ +0.21% | ▲ +0.27% | $13.87 (−0.93%) |
Oct 8, 2026 18d ago | 3 | $14.00 $14.03 | ▲ +0.21% | ▲ +0.27% | $13.87 (−0.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers